Cargando…

CAR-NK cells: A promising cellular immunotherapy for cancer

Natural Killer (NK) cells and CD8(+) cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating haematological malignancies, there is a rapid g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Guozhu, Dong, Han, Liang, Yong, Ham, James Dongjoo, Rizwan, Romee, Chen, Jianzhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452675/ https://www.ncbi.nlm.nih.gov/pubmed/32853984 http://dx.doi.org/10.1016/j.ebiom.2020.102975

Ejemplares similares

Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia
por: Dong, Han, et al.
Publicado: (2022)

CAR‐NK cell in cancer immunotherapy; A promising frontier
por: Marofi, Faroogh, et al.
Publicado: (2021)

Utilizing Cytokines to Function-Enable Human NK Cells for the Immunotherapy of Cancer
por: Romee, Rizwan, et al.
Publicado: (2014)

Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy
por: Tarannum, Mubin, et al.
Publicado: (2022)

Autologous cellular therapy for myeloma: Giving ex vivo expanded NK cells their due
por: Shapiro, Roman M., et al.
Publicado: (2022)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

CAR-NK cells for cancer immunotherapy: from bench to bedside
por: Zhang, Leisheng, et al.
Publicado: (2022)

Engineering the next generation of CAR-NK immunotherapies
por: Biederstädt, Alexander, et al.
Publicado: (2021)

NK cell-based immunotherapy for treating cancer: will it be promising?
por: Cho, Duck, et al.
Publicado: (2011)

CAR‐NK cells: the next wave of cellular therapy for cancer
por: Daher, May, et al.
Publicado: (2021)

Cytokine-induced memory-like natural killer cells for cancer immunotherapy
por: Tarannum, Mubin, et al.
Publicado: (2021)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
por: Wu, Xinyu, et al.
Publicado: (2022)

CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
por: Marofi, Faroogh, et al.
Publicado: (2021)

CAR-NK Cells: A Chimeric Hope or a Promising Therapy?
por: Sabbah, Mohamad, et al.
Publicado: (2022)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Retraction: CAR-NK Cell: a new paradigm in tumor immunotherapy
Publicado: (2023)

The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy
por: Sun, Haoyu, et al.
Publicado: (2019)

Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy
por: Schmidt, Dayane, et al.
Publicado: (2022)

Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy
por: Yang, Kangdi, et al.
Publicado: (2023)

The role of MSCs and CAR-MSCs in cellular immunotherapy
por: Yan, Lun, et al.
Publicado: (2023)

Technical advances in NK cell-based cellular immunotherapy
por: Fang, Fang, et al.
Publicado: (2019)

Manipulating NK cellular therapy from cancer to invasive fungal infection: promises and challenges
por: Oh, Bernice Ling Zhi, et al.
Publicado: (2023)

CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
por: Marofi, Faroogh, et al.
Publicado: (2021)

CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy
por: Hadiloo, Kaveh, et al.
Publicado: (2023)

DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy
por: Cifaldi, Loredana, et al.
Publicado: (2023)

The promise of adoptive cellular immunotherapies in hepatocellular carcinoma
por: Hendrickson, Peter G., et al.
Publicado: (2019)

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
por: Wang, Wei, et al.
Publicado: (2015)

Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T
por: Liu, Qiaofei, et al.
Publicado: (2023)

Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies
por: Krug, Adrien, et al.
Publicado: (2021)

Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies
por: Soldierer, Maren, et al.
Publicado: (2022)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer
por: Hu, Zhiwei
Publicado: (2020)

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
por: Burger, Michael C., et al.
Publicado: (2019)

CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review
por: Chan, Ler Yie, et al.
Publicado: (2022)

CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
por: Hovhannisyan, Lusine, et al.
Publicado: (2023)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients
por: Arnaud, Marion, et al.
Publicado: (2021)

Current Progress of CAR-NK Therapy in Cancer Treatment
por: Pang, Zhaojun, et al.
Publicado: (2022)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Herrera, Lara, et al.
Publicado: (2021)

P33. NK-92 cellular immunotherapy as an alternative to donor derived peripheral blood NK cells
por: Klingemann, H
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_acg6fvkmm2hcqea02idpf3paf6